Penumbra, Inc. vs Johnson & Johnson
PEN vs JNJ — side-by-side comparison from reported financials. PEN leads 2, JNJ leads 7 of 9 comparable metrics.
Penumbra, Inc.
PEN · Healthcare
$319.40+0.59%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | PEN | JNJ |
|---|---|---|
| Price | $319.40 | $261.79 |
| Market cap | $12.6B | $631B |
| Revenue (TTM) | $1.50B | $97.9B |
| Revenue growth | +18.3% | +5.6% |
| Net margin | 10.7% | 21.5% |
| Free cash flow | $216M | $22.2B |
| Net cash (debt) | — | ($27.8B) |
| 1-year price return | +22.2% | +37.0% |
| P/E | 78.3 | 29.9 |
| P/E vs own history (cheap-side %) | 76% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 11% | 26% |
| Altman Z-score | 18.49 | — |
| CV checks passed | 9 of 10 | 10 of 10 |
| Employees | 4,700 | 140,800 |
Full résumé-style profiles: PEN CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.